Eli Lilly settles with medical spa over its marketing of compounded tirzepatide

Eli Lil­ly reached a set­tle­ment with a South Car­oli­na med­ical spa, mark­ing a win in a broad­er le­gal cam­paign against how com­pounders have mar­ket­ed ver­sions of its di­a­betes and weight loss prod­ucts.

To­tal­i­ty Medis­pa in Charleston has agreed not to use Eli Lil­ly’s trade­marks, in­clud­ing in its mar­ket­ing of com­pound­ed ver­sions of tirzepatide. The drug is sold by Lil­ly un­der the brand names Moun­jaro and Zep­bound for di­a­betes and obe­si­ty, re­spec­tive­ly. To­tal­i­ty will make an undis­closed pay­ment and has com­mit­ted to “con­spic­u­ous­ly and promi­nent­ly” dis­clos­ing in all of its ad­ver­tise­ments that com­pound­ed tirzepatide is not FDA-ap­proved, ac­cord­ing to Lil­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.